Category: News

By Christopher Valasek, Joshua Cole, Frank Hensel, Pei Ye, Michael A. Conner, and Michiel E. Ultee Mmunoglobulin G (IgG) antibodies have been used to treat cancer for many years. Another class of antibodies — immunoglobulin M (IgM) — has been overlooked in spite of offering unique advantages that make them highly desirable as cancer therapeutics. Serving a valuable function in our innate immune system, IgM antibodies […]

DPx Holdings B.V., privately owned by JLL Partners and Royal DSM and the parent company of Patheon, announces that it has completed the transaction to acquire Gallus BioPharmaceuticals, LLC, a leading contract manufacturing company specializing in biologics. Patheon’s biologic drug substance business, a unit of DPx Holdings, now spans four global facilities in Europe, Australia and North America and includes more than 550 employees. “We […]

Durham, N.C. and St. Louis–(August 27,  2014)–DPx Holdings B.V., privately owned by JLL Partners and Royal DSM, is pleased to announce that it has reached a definitive agreement to acquire all shares of Gallus BioPharmaceuticals, LLC, a leading contract manufacturing company specializing in biologics and current portfolio company of Ridgemont Equity Partners. Following the transaction, Patheon’s biologic drug substance business, a unit of DPx Holdings, will […]

(St.Louis, Missouri, August 21, 2014)– Gallus BioPharmaceuticals, LLC, a premier, full service biopharmaceutical contract development and manufacturing organization (CMO) announced today that it has been selected by Progenics Pharmaceuticals, Inc., an oncology company focused on the development of innovative approaches to targeting and treating cancer, to manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal antibody used in Progenics’ PSMA ADC product candidate. Under the agreement […]

(St. Louis, MO, April 29, 2014) – Gallus BioPharmaceuticals, LLC (Gallus), a premier pure-play biologics contract development and manufacturing organization (CMO), and Omni Bio Pharmaceutical, Inc. (Omni Bio) (OMBP.ob), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, jointly announced finalization of a multi-stage […]

(St. Louis, Missouri – February 25, 2014)– Gallus BioPharmaceuticals, LLC (Gallus), a premier pure-play biologics contract manufacturing organization (CMO) has signed a manufacturing agreement with Symphogen, A/S (Symphogen), a private biopharmaceutical company developing recombinant monoclonal antibody (mAb) mixtures for the treatment of cancer. This agreement includes process transfer and clinical stage cGMP manufacturing of Symphogen’s antibody mixture product candidates. Gallus will employ the GE Healthcare […]

Gallus BioPharmaceuticals, LLC (Gallus), a premier pure-play biologics contract manufacturing organization (CMO) announces the appointment of Claudette Kile as Vice President of Quality & Regulatory. This addition to the highly experienced Gallus leadership team supports the continued growth of Gallus’ contract manufacturing services. Ms. Kile will be responsible for the planning, implementation and daily operations of the Quality & Regulatory organization at Gallus headquarters in […]

By Michiel E. Ultee, Ph.D., CSO Laureate Biopharma cell-culture scientists routinely develop cell-culture processes to produce higher titers of the desired recombinant protein over the original processes given to them by our clients. Increasing titer is one of the most effective routes to lower cost of goods for our clients. This is because titers can often be increased two to five fold, meaning that any […]

By Douglas W. Rea, Michiel E. Ultee, Sharon X. Chen, Thomas P. Loisel Platform processes are valuable tools in process development. Applying them to complex fusion molecules made up of different structures, however, can lead to unexpected results. EA2 is a unique engineered molecule, and it did not fit well into a platform process. It does, however, have three potential affinity and pseudo-affinity sites, each […]

(St. Louis, Missouri – October 1, 2013) – Gallus BioPharmaceuticals, LLC (Gallus), a leading biologics contract manufacturing organization (CMO), today announced its acquisition of Laureate Biopharmaceutical Services, Inc. (Laureate), a full service biologics CMO located in Princeton, New Jersey. This acquisition doubles Gallus’ process development (PD) and clinical drug substance manufacturing capacity, adds full protein characterization, testing and clinical fill-finish capability and offers a seamless development […]